BOARD OF DIRECTORS
Over the last 35 years, Barry has founded and managed several technology companies through to sale and IPO.
In 2012 he was treated as a patient at one of the founding scientist's clinic and subsequently began establishing the strategy to take his extraordinary therapies to a global market, before formally founding Micregen together in 2015.
Senior Lecturer in Acute & Emergency Care at Oxford Brookes University, Professor of Neuroscience at the Carrick Institute Florida, served as International Scientific Advisor to major South African and Swiss stem cell clinics and cell banks.
Steve has extensive experience in the clinical application of stem cell secretomes that extends over twenty five years. He has presented over one hundred papers at international scientific conferences with nineteen as the keynote speaker. He has already translated his research through to proven clinical practice.
Jim is a serial entrepreneur with a track record of success in the pharmaceutical industry. He has more than 35 years pharmaceutical industry experience.
Jim has led both Commercial and Research and Development teams across a number of pharma organisation. He has a demonstrable track record of success in Clinical Research, Life Sciences, and Strategic Planning.
Jim was a Founding Director of the Clinigen Group, a £1B market cap specialist pharmaceutical and supply company where he was head of business development at the time of the IPO.
Jo is a senior biopharmaceutical business development leader with extensive global commercial and general management experience and an outstanding record of strategy development, deal preparation and execution.
She enjoyed a long and successful career with AstraZeneca with a significant portion of her career working in business development. Her last role was VP Business Development - Head of Transactions.
Jo has diverse experience of leading buy and sell life sciences deals including M&A, licensing, collaboration and divestments. Her track record includes leading transformational, high value transactions.
Jo is passionate about innovation and building partnerships to bring new therapy options to patients.
A qualified USA Lawyer & UK Solicitor with an accounting, finance and risk management background, Cary has held positions of Compliance Director and Chief Risk Officer in the UK and USA across several sectors including biotech and medical device manufacturing.
Former Fellow and Chairman of the Institute of Risk Management, Cary has been an English solicitor since 1997 and a California lawyer since 1990.
Cary’s focus is to lead Micregen through the regulatory approvals process with support from Micregen’s advisory team.
Peter built his family business to an exit with over 400 shops nationwide, that was recognised as the largest Hearing Aid and Audiology provider in the UK.
Peter was also instrumental in the successful sale of the business to the Swiss Sonova Group and the subsequent part sale of the business to Boots the Chemist, including overseeing the rebrand to Boots Hearingcare that he went on to chair.
He was also actively involved in the regulation and governance of the hearing sector, a member of the Hearing Aid Council the government regulator at that time and subsequently a panel member of the Health and Care Professions Council. Peter continues to Chair the National Community Hearing Association.
In addition to his non-exec advisory role, Peter Chairs the Micregen remuneration Committee.